<DOC>
	<DOCNO>NCT00531336</DOCNO>
	<brief_summary>The first result Anti-Vascular Endothelial Growth Factor ( VEGF ) therapy promise superior establish therapy . Three different substance ( apply intravitreally ) available , comparative study yet conduct . In pilot study , safety ( number adverse event ) efficacy ( distance acuity test retinal thickness measurement ) Avastin Macugen apply monotherapy compare combined treatment Avastin follow Macugen use retreatment . At least equal result combine therapy expect .</brief_summary>
	<brief_title>MAAM Study : Avastin Macugen Versus Avastin Versus Macugen</brief_title>
	<detailed_description>The role Vascular Endothelial Growth Factor ( VEGF ) pathogenesis neovascular disease like choroidal neovascularization ( CNV ) proliferative diabetic retinopathy demonstrate series publication . Therefore intravitreally apply VEGF antagonist use treatment CNV age-related macular degeneration ( AMD ) diabetic case . Three anti-VEGFs available : Macugen® ( Pegaptanib ) , Avastin® ( Bevacizumab ) Lucentis® ( Ranibizmab ) . Pegaptanib sodium aptamer design bind VEGF 165 isoform high affinity . Bevacizumab humanize monoclonal antibody VEGF design intravenous administration approve treatment colorectal cancer . Ranibizumab anti-body binding site fragment derive anti-VEGF antibody bevacizumab . The decrease retinal thickness measure OCT provide information concern amount intraretinal fluid accumulation therefore activity neovascular lesion . It proven aqueous humor level VEGF eye CNV significantly high eye without ocular systemic disease . The retinal thickness VEGF concentration aqueous humor give good correlation anti vasogenic effect intravitreal treatment . In study bevacizumab pegaptanib monotherapy compare combined therapy bevacizumab apply first pegaptanib use retreatment . The benefit combine therapy initial blockage VEGF isoforms necessary whereas retreatment blockage important isoform pathogenesis CNV sufficient normal function retinal pigment epithelium choriocapillaris affect .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age &gt; 50 year Predominantly occult CNV Greatest diameter lesion &lt; 5400µm Distance acuity &gt; 0.1 Complicating general disorder inflict heal process Vision threatening disease CNV Prior treatment CNV Ophthalmic surgery within 4 week Not consent patient</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>age-related Macular degeneration</keyword>
	<keyword>Macugen</keyword>
	<keyword>Avastin</keyword>
</DOC>